Skip to content
Head to head

Indivior vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: INDV · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

INDV +15.6%TAK +50.1%
Indivior edges it on the scoreable measures. Indivior trades cheapest on trailing earnings; Indivior earns the most per share.
INDVTAK
Snapshot
Sector----
Last price0.0021.77
Change today+2.57%+1.68%
1-year return+23.5%+57.5%
Market cap$4.28B$69.76B
52-week range0.00 – 0.0013.92 – 22.07
Valuation
P/E (TTM)10.16311.00
P/E percentile, own 5-yr range46th100th
P/B-71.421.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)1.64-0.30
Net profit (TTM)$193.58M$-970.94M
Revenue (TTM)$1.37B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+13.4%+6.7%
Gross margin84.9%65.8%
Operating margin41.0%14.3%
Net margin32.8%0.9%
Free cash flow (TTM)$31.00M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership104.5%51.3%
Insider activity (12mo)39 buy / 11 sell19 buy / 31 sell
Short interest (% of float)8.0%0.1%
Analyst consensus100% buy (3)100% buy (1)
Analyst price target$47$50 (+132%)
StockVane view
StockVane Quant RatingC (54)C (90)
Company
Employees83847,029
Founded20141781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.